Human immunodeficiency virus (HIV) type 1 integrase (IN) active site, and viral DNA-binding residues K156 and K159 are predicted to interact both with strand transfer-selective IN inhibitors (STI), e.g. L-731,988, Elvitegravir (EVG), and the FDA-approved IN inhibitor, Raltegravir (RGV), and strand transfer non-selective inhibitors, e.g. dicaffeoyltartaric acids (DCTAs), e.g. L-chicoric acid (L-CA). To test posited roles for these two lysine residues in inhibitor action we assayed the potency of L-CA and several STI against a panel of K156 and K159 mutants. Mutagenesis of K156 conferred resistance to L-CA and mutagenesis of either K156 or K159 conferred resistance to STI indicating that the cationic charge at these two viral DNA-binding residues is important for inhibitor potency. IN K156N, a reported polymorphism associated with resistance to RGV, conferred resistance to L-CA and STI as well. To investigate the apparent preference L-CA exhibits for interactions with K156, we assayed the potency of several hybrid inhibitors containing combinations of DCTA and STI pharmacophores against recombinant IN K156A or K159A. Although K156A conferred resistance to diketo acid-branched bis-catechol hybrid inhibitors, neither K156A nor K159A conferred resistance to their monocatechol counterparts, suggesting that bis-catechol moieties direct DCTAs toward K156. In contrast, STI were more promiscuous in their interaction with K156 and K159. Taken together, the results of this study indicate that DCTAs interact with IN in a manner different than that of STI and suggest that DCTAs are an attractive candidate chemotype for development into drugs potent against STI-resistant IN.
As part of a study of the medicinal plants of the Kallawaya herbalists of Bolivia [1] , sixty species were examined for their anti-HIV activity [2] . Bioassay directed isolation identified two active dicaffeoylquinic acids from Achyrocline satureioides and Baccharis genistelloides [1, 3] . Testing of these compounds and a synthetic analogue, L-chicoric acid (L-CA) (Figure 1 ), revealed the first example of anti-HIV activity due to inhibition of HIV-integrase [3] .
The FDA-approval of the human immunodeficiency virus type 1 (HIV-1) integrase (IN) inhibitors Raltegravir (RGV) and Elvitegravir (EVG) expands therapeutic options for patients infected with HIV; however, patients failing therapy with RGV are reported to fail EVG therapy as well [4] . Development of new inhibitors potent against both RGV-and EVG-resistant HIV is necessary for continued therapeutic exploitation of IN. Rational, structure-guided drug design of IN inhibitors has been hampered by the poorly soluble, structurally intractable nature of full-length native HIV IN [5] . Although co-crystal structures [6] [7] [8] of an orthologous IN from prototype foamy virus (PFV, a spumavirus subfamily member) complexed with viral DNA, metal ion cofactors, RGV or EVG offer insight into retroviral integration and inhibitor mechanisms, there is considerable sequence disparity, notably in the extracatalytic domains, between PFV and HIV IN. In lieu of HIV IN structure-guided inhibitor design, structure-activity relationship studies of active compounds coupled with IN mutagenesis, guided in part by computer modeling, provides alternative strategy for drug discovery and development.
IN is essential for the covalent end-joining of the retroviral cDNA genome into the host cellular genome -a multistep biochemical process collectively termed integration. Integration is required for stable and productive infection of the target cell [9] . Integration biochemistry is described in three steps (reviewed in [10] ); i) 3'-end processing, ii) strand transfer, and iii) 5'-end joining. In the host cytosol IN binds conserved CpA dinucleotide motifs found in both 3' termini of the viral long terminal repeats (LTRs). IN cleaves terminal GpT dinucleotides from the 3' ends, exposing free 3'hydroxyl groups. Following 3'-end processing, pre-integration complexes (PIC), containing IN, the cDNA genome, and several other host and viral cofactors (reviewed in [11] ) translocate into the host cell nucleus. Inside the nucleus, IN mediates a concerted cleavage-ligation reaction, directing the nucleophilic attack of the free 3'-hydroxyls onto opposing phosphodiester backbone strands of the host genomic DNA at a distance spaced 5 bases apart. This reaction is termed strand transfer and generates a gapped intermediate product. In the final step of integration, the gaps flanking the partially integrated HIV genome are repaired by host cellular DNA repair enzymes, producing a fully integrated provirus flanked by 5 base pair direct repeats.
IN is a 288 amino acid, 32 kDa protein structurally orthologous to integrases from bacterial and yeast retrotransposons, RuvC, and RNase H [12] . HIV IN contains three domains: the N-terminal domain (NTD), core catalytic domain (CCD), and C-terminal domain (CTD). The NTD, containing amino acids 1-49, contains an HHCC zinc-binding motif important for protein folding [13] , multimerization [14] [15] [16] , and virion morphology [17, 18] . The CCD, containing amino acids 50-212, contains a DDX 35 E motif that coordinates a required divalent metal cation (Mg 2+ or Mn 2+) cofactor essential for catalysis [19, 20] . The arginine-rich CTD, containing amino acids 213 to 288, contains a Src homology 3 (SH3)-like subdomain [21, 22] and binds DNA in a sequence non-specific manner [23] [24] [25] [26] . Deletion of the NTD, CTD or both the NTD and CTD does not abolish all IN catalytic activities [25] ; however, deletion or mutation of any one of the core catalytic triad residues results in catalytically-inactive IN, indicating that the catalytic machinery resides within the CCD [27] [28] [29] .
In silico modeling based on available structural and biochemical data generates testable hypotheses for a diverse range of IN inhibitors including: dicaffeoyltartaric acids (DCTAs) e.g. Lchicoric acid [30] [31] [32] [33] , β-diketo acids (DKAs) e.g L-731,988 [34] [35] [36] , and the two clinical inhibitors, RGV and EVG [37] [38] . DKAs, RGV, and EVG selectively inhibit strand transfer (strand transfer inhibitors, termed STI), while L-CA inhibits both strand transfer and 3'-end processing at equimolar concentrations. In addition, STI require IN-metal ion-viral DNA complex assembly [39] for high affinity binding while L-CA can bind to IN in the absence of metal ions or DNA [40] . Taken together, these inhibitor attributes suggest that STI and L-CA have different mechanisms of action. We chose to test predicted roles of K156 and K159 in inhibitor action for several reasons: 1) in the only reported HIV IN-inhibitor co-crystal structure [41] both K156 and K159 are proximal to the DKA analog, 5-CITEP; 2) K156 and K159 are implicated in both STI and L-CA binding suggesting that these two lysines are involved in an overlapping mechanism of inhibitor action; and 3) K156 and K159 cross-link to the viral DNA 3'-end containing the conserved 5'-CpA-OH motif [42] [43] [44] [45] and the PFV IN ortholog to K159 (PFV IN K228) is shown bound directly to the phosphate backbone in the 5'-CpA-OH motif [7, 46] suggesting that K156 and K159 are directly involved in orienting the viral DNA donor strand during catalysis; and 4) polymorphisms at residue 156 are associated with resistance to RGV [47] and are found within multiple clades of HIV [47] [48] [49] [50] . We substituted K156 and K159 with increasingly non-conservative arginine, alanine, and aspartate residues and predicted that these mutations would confer increasing resistance to a spectrum of IN inhibitors, perhaps to the detriment of enzyme activity.
Since mutagenesis of either K156 or K159 confers reduced enzyme activities, the 3'-end processing and strand transfer specific activities for recombinant IN K156 and K159 mutants were assayed. Recombinant IN from HIV NL4-3 was employed as a reference. Representative assays are shown in Figure 2 . Arginine or alanine substitution had a relatively mild effect on 3'-end processing as K156R/A or K159R/A conferred approximately 50 percent or greater reference activity ( Figure 3 ). Exchanging the cationic charge of K156 with polar asparagine, as is the case with the polymorphism, K156N, had little effect on 3'-end processing activity. In contrast, aspartate substitution strongly attenuated 3'end processing activity as K156D or K159D conferred approximately 2 percent of reference activity. The effects of mutations on strand transfer were generally consistent in trend with those observed for 3'-end processing, although the degree of strand transfer attenuation was more pronounced.
Mutagenesis of K156 confers resistance to both L-CA and L-731,988, while mutagenesis of K159 primarily confers resistance to L-731,988. To test predictions that K156 and K159 are involved in inhibitor action, the sensitivities of recombinant IN K156R/N/A/D and K159R/A/D to L-CA, L-731,988, RVG, and EVG were determined. The strand transfer inhibitory potency of each compound was determined for each STI and both strand transfer and 3'-end processing potencies were determined for L-CA. In 3'-end processing assays, K159A and K159R conferred mild, yet significant resistance and K156A and K156R conferred 10 and 5-fold (respectively) resistance to L-CA ( Table 1 ). The effects of mutations on L-CA-mediated inhibition of strand transfer were generally commensurate with those observed in 3'-end processing assays. L-731,988 demonstrated low nanomolar potency against reference IN-mediated strand transfer; however, arginine, asparagine, alanine, or aspartate substitution of K156 or K159 conferred between 11-and 190-fold resistance to the DKA ( Figure  4 and Table 1 ).
Mutagenesis of K156 or K159 confers resistance to RGV and EVG.
In PFV IN-DNA co-crystal structures [27, 29] , RGV and EVG coordinate the IN active site metal ion cofactor π-π stack with the proxy-terminal deoxycytosine base in the viral DNA donor strand, thus deflecting the terminal 3' deoxyadenosine base away from the presumed site of strand transfer catalysis. Increasingly, non-conservative substitution of K156 or K159 generally conferred increased resistance to RGV: K156R/N/A/D conferred 6-, 3-, 8-, and 12-fold resistance (respectively), and K159R/A/D substitutions conferred 2-, 6-, and 5-fold resistance to RGV (Table 1) . Although EVG was tolerant of the loss of cationic charge at either lysine position, the introduction of anionic charge conferred significant resistance to EVG: K156D conferred 7-fold resistance and K159D conferred 9-fold resistance to EVG.
Mutagenesis of both K156 and K159 to alanine impairs catalysis and confers resistance to L-CA, L-731,988, RGV, and EVG. To determine if there is functional cooperation between the two lysine residues, a double alanine mutant, K156A-K159A, was evaluated. Given the close proximity of the two residues residing on the same face of α-helix 4, we postulated that the functional role of K156 may be assumed by K159 (and vice versa) should the cationic charge at either position be lost. Finding that increasingly nonconservative substitution of either K156 or K159 was commensurate with increasingly defective enzyme activity ( Figure  3) , it was evident that the presence and type of cationic charge at positions 156 and 159 directly influences enzyme activity. We predicted that removal of both cationic charges should reduce catalytic activity more than removal of either charge alone. For 3'-end processing activity, this did indeed appear to be the case; K156A-K159A conferred greater defects to defective 3'-end processing specific activity than did either K156A or K159A alone ( Figure 3 ). In strand transfer assays, however, the K156A-K159A exhibited equal activity to K156A alone, perhaps suggesting that cationic charge at K156 is preeminent to charge at K159 for strand transfer.
Along similar lines or reasoning for the cooperative impact of K156A-K159A on enzyme activity, we also hypothesized that K156A-K159A would enhance inhibitor resistance conferred by either mutation alone, possibly with synergistic effect. Although 6A-K159A did confer significant resistance to all four inhibitors, no indication of synergy was observed ( Table 1) . Excluding EVG, the degrees of resistance conferred by K156A-K159A were generally less than those observed for each single point mutant. IN K156A-K159A did confer greater resistance to EVG than did K159A (K156A conferred greater sensitivity to the inhibitor); however, this mild increase is not consistent with synergy.
Biscatechols direct DCTAs toward interactions with K156.
Observing that K156A conferred resistance to L-CA and L-731,988, and K159A conferred resistance to L-731,988, but not to L-CA, we hypothesized that chemical motifs unique to L-CA, e.g. catechols (Figure 1 ), were responsible for this apparent bias between K156 and K159: biscatechols direct interaction to K156, monocatechol directs interaction to K159. To test these hypotheses, a small panel of hybrid inhibitors containing combinations of catechols and the pharmacophore of DKAs ( Table 2 , compounds 1-6) were assayed. In addition, the carboxylate of several of these compounds ( Table 2 , compounds 2, 4 and 6) was methylated to test each compound's potential for salt bridge formation between the β-diketo acid moiety and the basic amines of K156 and K159. It was postulated that molecules resembling L-CA, e.g. branched, containing two catechol groups (compounds 1-2), would interact principally with K156, while molecules containing one catechol (compounds 3-6), resembling the more planar inhibitors, e.g. L-731,988 and 5-CITEP, would interact principally with K159. Compound 7, an analog of L-731,988 [51] , was assayed to determine if the composition of the aryl group(s) adjacent to the DKA group modulates interaction with K156 and K159. 5-CITEP was assayed to test predictions made in several models [36, 52, 53] and to determine if the position of the inhibitor observed in the crystallographic data [7] is biochemically relevant. The strand transfer potency of compounds 1-7 and 5-CITEP were determined to facilitate comparison between STI. Although IN mutagenesis studies including K156 and K159 are reported [43, 51, [54] [55] [56] [57] , we present a focused and more expansive investigation of the role of K156 and K159 in inhibitor potency and enzyme activities. Comparison of biochemical analyses of IN enzyme activities and inhibitor sensitivities across different studies can be confounded by the range of interlaboratory materials and methods; for example, the selection of metal ion cofactor [58] , the concentration of salt employed in biochemical assays, and protocols for recombinant protein expression and purification. Nevertheless, previous studies are largely in accord with the present work. IN K159P significantly delays viral replication [54] , suggesting that this helix-breaking substitution disrupts critical secondary structures within the active site. K156E or K159E mutations confer HIV replication-incompetence and severely attenuate recombinant IN activities [45] . Although IN K156E and K159E disrupt viral DNAbinding, they do not hamper in vitro IN multimer formation or nonspecific DNA binding [45] , suggesting that the primary role of these cationic residues is to orient properly the viral DNA during catalysis. Herein, arginine, alanine, and aspartate substitution of K156 and K159, in this order, had an increasingly deleterious effect on all three catalytic functions, reinforcing the notion that the presence and type of cationic charge is necessary for efficient catalysis. Aspartate mutations at either residue had a far more deleterious effect on enzyme catalysis than did alanine substitution at both residues, suggesting that introducing an anionic charge adjacent to the neighboring lysine residue can be ascribed to more than charge neutralization alone. These acidic residues may repel the DNA substrate or disrupt metal coordination within the active site.
Computer modeling [30] [31] [32] [33] predicts that L-CA straddles the active site, the phenolic hydroxyls hydrogen bond with Q148 and E92 (albeit more favorably with Q148 [33] ) and the carboxylates form salt bridges with K156 and K159 (and possibly hydrogen bond with the protonated backbone amine of H67 [33] ). Modeling also predicts that L-CA makes extensive van der Waals contacts with several residues including C65, T66, and catalytic triad members D64 and E152. IN Q148A, E92K, or T66I mutations confer resistance to L-CA [31, 40] , lending empirical evidence to support these computer-modeled interactions. Herein, mutagenesis of K156
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The impact of K156 and K159 substitutions on STI potency (L-731,988, RGV, and EVG) were largely dependent on the presence of cationic charge at either lysine position, suggesting that the DNA-binding activities of these two lysine residues are important for STI action. The observation that many STI, including L-731,988 and L-870,810, bind IN with high affinity and inhibit strand transfer [39, 59] only after formation of an IN-DNA complex suggests a common mechanism of action in which STI trap the IN-DNA synaptic complex in a strand transfer-incompetent state [60] . Thus, mutations that reorient the viral DNA are likely to preclude efficient STI binding. Crystal structures of PFV IN containing primary RGV and EVG resistance mutations G140S, Q148H, and N155H indicate that resistance is conferred via the cooperative action of multiple allosteric shifts in the active site resulting in less energetically favorable STI binding [61] . STI resistance is believed to be conferred not by lost direct interactions between IN and the drug, but through allosteric retuning of the active site. It is plausible that mutations at K156 and K159 confer resistance to L-CA and STI via similar allosteric mechanisms as described for G140S, Q148H, and N155H. HIV IN K156 crosslinks to viral DNA [45] and, herein, mutagenesis of K156 conferred resistance to STI suggesting that K156, like K159, may also be involved in viral donor strand positioning within the active site during strand transfer. Finding that K156N conferred significant resistance to inhibitors and was the least deleterious of the noncationic substitutions suggests a rationale for its reported isolation [47] alongside other mutations shown to confer resistance to RGV in patients [4, 62] .
The data suggest that bis-catechols direct β-diketo acid-containing hybrid compounds to interact specifically with K156. The potencies of compounds 1 and 2 are consistent with this hypothesis, suggesting that these two hybrids may bind the active site in a manner similar to that predicted for L-CA. The methylated variant, compound 2, exhibited similar potency to its unmethylated counterpart, indicating that, for biscatechols, methylation does not influence the interaction with either lysine residue. In contrast, methylation significantly influenced inhibitor interactions for the monocatechol variants, compounds 3 and 5, which remained potent against both K156A and K159A, while their methylated counterparts, compounds 4 and 6, lost potency against K156A. Although compounds 3-6 exhibit a planar geometry similar to L-731,988, 5-CITEP and compound 7, their sustained potency against recombinant IN K159A suggests they interact with IN in a unique manner. Furthermore, compounds 1-6 are not STI [63] , suggesting that their mechanism of inhibition is different than that of L-731,988, 5-CITEP, or compound 7. Considering that compounds 3 and 5 maintained potency against both K156A and K159A, these two inhibitors may be attractive candidates for development into next-generation inhibitors potent against STI-resistant HIV.
In summary, the study herein demonstrates the importance of residues K156 and K159 in the action of several classes of HIV IN inhibitors. The results suggest that STI are more promiscuous than the catalytically non-selective DCTAs in their binding modes. The data also suggest that bis-catechols, and perhaps other DCTA-like chemotypes form an attractive scaffold for the construction of second generation inhibitors potent against STI-resistant HIV, at least those that contain mutations at K159.
Experimental
Inhibitors: L-CA, L-731,988, RGV, EVG, compounds 1-7, and 5-CITEP were synthesized based on published procedures (L-CA [64] , L-731,988 [65] , RGV [66] , EVG [67] , compounds 1-6 [63] , compound 7 [68] , and 5-CITEP [69] ) and certified >99% pure by elemental analysis and/or nuclear magnetic resonance spectroscopy. The structures of L-CA, L-731,988, 5-CITEP, RGV, and EVG are shown in Figure 1 .
Oligonucleotides: All oligonucleotides were synthesized and desalted by Integrated DNA Technologies (Coralville, IA). Oligonucleotides used for enzymatic assays, V1, V2, and U5V1P [31] were subsequently gel purified prior to use ( Supplemental  Table S1 ).
Mutagenesis and cloning of IN genes:
Mutated IN genes were generated using the QuikChange® XL site-directed mutagenesis kit (Agilent, Santa Clara, CA) using oligonucleotide primers ( Supplemental Table S1 ) and IN from HIVNL4-3 (GeneBank Accession #M19921, nt4229 to nt5096). Mutagenesis was confirmed by fluorophore-labeled dideoxynucleotide chainterminating DNA sequencing (GeneWiz, La Jolla, CA) in both directions. Each IN gene was cloned into the recombinant protein expression vector, pT7.7, using engineered silent restriction endonuclease sites, as described previously [31, 70] .
Generation of recombinant IN proteins: Recombinant IN proteins
were expressed in BL21 DE3 pLysS Escherichia coli (Agilent, Santa Clara, CA) and purified from inclusion bodies following bacterial lysis, as described previously [31, 70] . Purity was confirmed > 95% via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by staining with coomassie blue dye. Recombinant IN proteins were resolved to a MW of approximately 32 kDa (data not shown).
Fractions containing purified IN were pooled and dialyzed into storage buffer {20 mM HEPES pH 7.5, 300 mM NaCl, 5 mM CHAPS, 10% glycerol, and 5 mM dithiothreitol (DTT)} then stored at -80 o C.
Determination of recombinant IN specific activities:
3'-End processing and strand transfer specific activities of recombinant IN proteins were assayed as described previously [31, 70] . For each of the following oligonucleotides, bases underlined in boldface indicate the conserved 5'-CpA-3' dinucleotide motif found in the viral DNA ends. To measure 3'-end processing activity, the 5' [γ-32 P] radiolabeled, V1 (5'ATGTGGAAAATCTCTAGCAGT 3') was annealed to V2 (5' ACTGCTAGAGATTTTCCACAT 3'), to yield the duplex V1/V2 substrate. To determine strand transfer activity independent of 3'-end processing, [γ-32 P] radiolabeled U5V1P (5' ATGTGGAAAATCTCTAGCA 3') was annealed to oligonucleotide V2 to yield the duplex U5V1P/V2 substrate. Increasing concentrations of recombinant IN were incubated with 100 fmol radiolabeled substrate in 20 μL reaction volumes containing 20 mM HEPES, pH 7.5, 7.5% DMSO, 10 mM MnCl 2 , 20 mM NaCl, 0.5% Nonidet P-40, and 10 mM DTT. The reactions were incubated at 37 o C for 1 h, terminated via addition of EDTA (pH 8.0) to 50 mM and formamide to 30% (v/v), resolved via denaturing PAGE, then visualized and quantified via phosphorimager analysis (GE Healthcare, Sunnyvale CA).
Specific activities:
These were determined via linear regression analysis through the linear range of a plot of pmol IN versus fmol products.
IC 50 determination:
The IN inhibitor sensitivities of each recombinant protein were determined as described previously [31, 70] . Briefly, triplicate sets of 20 μL reactions containing 100 nM recombinant IN and 5 nM radiolabeled substrate were supplemented with increasing concentrations of inhibitor and incubated at 37 o C for 1 h. Additional buffer components were identical to those described above for specific activity assay. The reactions were then terminated, resolved, visualized and quantified via phosphorimager analysis as described above for specific activity determination. CalcuSyn software for Windows was used to calculate the compound IC 50 based on the percent inhibition relative to untreated controls at each inhibitor concentration. Table of oligonucleotides used for  mutagenesis. 
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